Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Partially-Blinded, Randomized, 24-Week, Parallel-Group, Non-Inferiority, Open-Label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma
Brief Summary: The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium in uncontrolled moderate to severe asthmatic patients.

The planned duration of treatment in this study was 24 weeks, followed up by a 7-day follow-up period.


Options:
A: Arm Label: GW685698X (fluticasone furoate) 100mcg Morning; Type: EXPERIMENTAL; Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Morning | Arm Label: GW685698X (fluticasone furoate) 100mcg Evening; Type: EXPERIMENTAL; Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Evening | Arm Label: GW685698X (fluticasone furoate) 250mcg Evening; Type: EXPERIMENTAL; Interventions: Drug: GW685698X (fluticasone furoate) 250mcg Evening | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Morning, Drug: GW685698X (fluticasone furoate) 100mcg Evening, Drug: GW685698X (fluticasone furoate) 250mcg Evening, Drug: Placebo | Intervention Type: DRUG; Name: GW685698X (fluticasone furoate) 100mcg Morning; Assigned to Arm(s): GW685698X (fluticasone furoate) 100mcg Morning, Placebo | Intervention Type: DRUG; Name: GW685698X (fluticasone furoate) 100mcg Evening; Assigned to Arm(s): GW685698X (fluticasone furoate) 100mcg Evening, Placebo | Intervention Type: DRUG; Name: GW685698X (fluticasone furoate) 250mcg Evening; Assigned to Arm(s): GW685698X (fluticasone furoate) 250mcg Evening, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: FLAMBOYANT 200/12; Type: EXPERIMENTAL; Interventions: Drug: Flamboyant 200/12, Other: Budesonide / Formoterol 400/12 Placebo | Arm Label: Budesonide/formoterol 400/12; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide / Formoterol 400/12, Other: Flamboyant 200/12 Placebo | Intervention Type: DRUG; Name: Flamboyant 200/12; Assigned to Arm(s): FLAMBOYANT 200/12 | Intervention Type: DRUG; Name: Budesonide / Formoterol 400/12; Assigned to Arm(s): Budesonide/formoterol 400/12 | Intervention Type: OTHER; Name: Flamboyant 200/12 Placebo; Assigned to Arm(s): Budesonide/formoterol 400/12 | Intervention Type: OTHER; Name: Budesonide / Formoterol 400/12 Placebo; Assigned to Arm(s): FLAMBOYANT 200/12
C: Arm Label: FF 100mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate, Drug: albuterol/salbutamol | Arm Label: FF 200mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate, Drug: albuterol/salbutamol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): FF 100mcg once daily, FF 200mcg once daily | Intervention Type: DRUG; Name: albuterol/salbutamol; Assigned to Arm(s): FF 100mcg once daily, FF 200mcg once daily
D: Arm Label: QVM149 150/50/80 μg; Type: EXPERIMENTAL; Interventions: Drug: QVM149 | Arm Label: QVM149 150/50/160 μg; Type: EXPERIMENTAL; Interventions: Drug: QVM149 | Arm Label: Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/fluticasone plus tiotropium | Intervention Type: DRUG; Name: QVM149; Assigned to Arm(s): QVM149 150/50/160 μg, QVM149 150/50/80 μg | Intervention Type: DRUG; Name: Salmeterol/fluticasone plus tiotropium; Assigned to Arm(s): Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg

Answer: D